The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...
The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...
The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV ... and demonstrated that a single dose of the live-attenuated IXCHIQ ® ...
The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus ... that a single dose of the live-attenuated IXCHIQ® vaccine induces ...
for the world’s first and only chikungunya vaccine, IXCHIQ ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results